885518-92-3

Basic information

• Product Name: 3-IODO-5-METHYL (1H)INDAZOLE
• Synonyms: 3-IODO-5-METHYL (1H)INDAZOLE;3-iodo-5-methyl-1H-indazole(SALTDATA: FREE);1H-INDAZOLE,3-IODO-5-METHYL-;3-iodo-5-methyl-2H-indazole
• CAS NO: 885518-92-3
• Molecular Formula: C8H7IN2
• Molecular Weight: 258.06
• Product Categories: Building Blocks;Indazole
• Mol File: 885518-92-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 368.6 °C at 760 mmHg
• Flash Point: 176.7 °C
• Appearance: /
• Density: 1.933g/cm³
• Vapor Pressure: 2.66E-05mmHg at 25°C
• Refractive Index: 1.749
• CAS DataBase Reference: 3-IODO-5-METHYL (1H)INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-IODO-5-METHYL (1H)INDAZOLE(885518-92-3)
• EPA Substance Registry System: 3-IODO-5-METHYL (1H)INDAZOLE(885518-92-3)

Safety Data

• Hazardous Substances Data: 885518-92-3(Hazardous Substances Data)

Usage

General Description

3-Iodo-5-methyl (1H)indazole is a chemical compound that belongs to the indazole class. It is a derivative of indazole, an aromatic heterocyclic organic compound with a molecular structure containing a five-membered ring with two nitrogen atoms. The presence of the iodo and methyl groups in the molecule gives it specific properties and potential applications in pharmaceutical and research settings. It may have potential applications as a building block in the synthesis of pharmaceuticals or as a reagent in organic chemistry reactions. Its specific physical and chemical properties make it a potential candidate for use in the development of various compounds for medicinal or research purposes.

InChI:InChI=1/C8H7IN2/c1-5-2-3-7-6(4-5)8(9)11-10-7/h2-4H,1H3,(H,10,11)

Upstream product

• 1776-37-0 5-methyl-1H-indazole 

Downstream Products

• 57614-16-1 3-phenyl-5-methyl-1H-indazole 

Relevant articles and documents

Synthesis and Biological Evaluation of 3-Arylindazoles as Selective MEK4 Inhibitors

Herein we report the discovery of a novel series of highly potent and selective mitogen-activated protein kinase kinase 4 (MEK4) inhibitors. MEK4 is an upstream kinase in MAPK signaling pathways that phosphorylates p38 MAPK and JNK in response to mitogenic and cellular stress queues. MEK4 is overexpressed and induces metastasis in advanced prostate cancer lesions. However, the value of MEK4 as an oncology target has not been pharmacologically validated because selective chemical probes targeting MEK4 have not been developed. Optimization of this series via structure–activity relationships and molecular modeling led to the identification of compound 6 ff (4-(6-fluoro-2H-indazol-3-yl)benzoic acid), a highly potent and selective MEK4 inhibitor. This series of inhibitors is the first of its kind in both activity and selectivity and will be useful in further defining the role of MEK4 in prostate and other cancers.

New CRTh2 antagonists.

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

Identification of potent ITK inhibitors through focused compound library design including structural information

A series of novel compound libraries inhibiting interleukin-2 inducible T cell kinase (ITK) were designed, synthesized and evaluated. In the first design cycle two library scaffolds were identified showing low micromolar inhibition of ITK. Further iterative design cycles including crystal structure information of ITK and structurally related kinases led to the identification of indolylindazole and indolylpyrazolopyridine compounds with low nanomolar ITK inhibition.